Abstract:Aptamers are short single-strand oligonucleotides that can form secondary and tertiary structures, fitting targets with high affinity and specificity. They are so-called "chemical antibodies" and can target specific biomarkers in both diagnostic and therapeutic applications. Systematic evolution of ligands by exponential enrichment (SELEX) is usually used for the enrichment and selection of aptamers, and the targets could be metal ions, small molecules, nucleotides, proteins, cells, or even tissues or organs. Due to the high specificity and distinctive binding affinity of aptamers, aptamer-drug conjugates (ApDCs) have demonstrated their potential role in drug delivery for cancer-targeting therapies. Compared with antibodies which are produced by a cell-based bioreactor, aptamers are chemically synthesized molecules that can be easily conjugated to drugs and modified; however, the conventional ApDCs conjugate the aptamer with an active drug using a linker which may add more concerns to the stability of the ApDC, the drug-releasing efficiency, and the drug-loading capacity. The function of aptamer in conventional ApDC is just as a targeting moiety which could not fully perform the advantages of aptamers. To address these drawbacks, scientists have started using active nucleotide analogs as the cargoes of ApDCs, such as clofarabine, ara-guanosine, gemcitabine, and floxuridine, to replace all or part of the natural nucleotides in aptamer sequences. In turn, these new types of ApDCs, aptamer nucleotide analog drug conjugates, show the strength for targeting efficacy but avoid the complex drug linker designation and improve the synthetic efficiency. More importantly, these classic nucleotide analog drugs have been used for many years, and aptamer nucleotide analog drug conjugates would not increase any unknown druggability risk but improve the target tumor accumulation. In this review, we mainly summarized aptamer-conjugated nucleotide analog drugs in cancer-targeting therapies.

Molecular Engineering‐Based Aptamer–Drug Conjugates with Accurate Tunability of Drug Ratios for Drug Combination Targeted Cancer Therapy

Polymeric Engineering of Aptamer-Drug Conjugates for Targeted Cancer Therapy.

Stimuli-Responsive Aptamer-Drug Conjugates for Targeted Drug Delivery and Controlled Drug Release

Automated Modular Synthesis of Aptamer–Drug Conjugates for Targeted Drug Delivery

Programmable Circular Multispecific Aptamer-Drug Engager to Broadly Boost Antitumor Immunity

Small molecule-drug conjugates: A novel strategy for cancer-targeted treatment

Modularly Engineered Solid-Phase Synthesis Of Aptamer-Functionalized Small Molecule Drugs For Targeted Cancer Therapy

A Basic Insight into Aptamer-Drug Conjugates (Apdcs).

Engineering Circular Aptamer Assemblies with Tunable Selectivity to Cell Membrane Antigens in Vitro and in Vivo.

Small Molecule‐Drug Conjugates: Opportunities for The Development of Targeted Anticancer Drugs

Molecular assembly of an aptamer-drug conjugate for targeted drug delivery to tumor cells.

Construction of Bispecific Aptamer–Drug Conjugate by a Hybrid Chemical and Biological Approach

A polyvalent aptamer system for targeted drug delivery

Recent Progress of Aptamer‒drug Conjugates in Cancer Therapy

Aptamer nucleotide analog drug conjugates in the targeting therapy of cancers

Building a Multifunctional Aptamer-Based DNA Nanoassembly for Targeted Cancer Therapy.

Aptamers Entirely Built from Therapeutic Nucleoside Analogues for Targeted Cancer Therapy.

Advances In The Development Of Aptamer Drug Conjugates For Targeted Drug Delivery

Self-Assembled Multivalent Aptamer Drug Conjugates: Enhanced Targeting and Cytotoxicity for HER2-Positive Gastric Cancer

Advances in the Development of Aptamer Drug Conjugates for Targeted Drug Delivery.

Aptamers as Smart Ligands for Targeted Drug Delivery in Cancer Therapy